Innovation Pharmaceuticals Inc (IPIX)

[mdphd2008]

Equal number of patients in both groups died.

However, more patients were treated with Brilacidin.

By definition, As a percentage of patients treated, the mortality was decreased in the Brilacidin group.

Secondary end points can be very valuable in designing future studies if safety criteria was met.

Of course, I would have been more ecstatic if primary endpoint was met.